Vogelstein: Onto liquid biopsies - for metastatic disease, 'works beautifully'. Problem is w/localized disease - 30-50% detection. #AACR17
11:50am April 2nd 2017 via Hootsuite
Vogelstein: First two, nothing can be done at present; the other two, chemoprevention, early detection. #AACR17
11:48am April 2nd 2017 via Hootsuite
Vogelstein: Random causes: quantum effects of base pairing, polymerase effects; hydrolytic deamination, also endogenous ROS #AACR17
11:47am April 2nd 2017 via Hootsuite
Vogelstein: Why impt? The first step in any war is to determine where the enemy is located. Primary prevention. #AACR17
11:45am April 2nd 2017 via Hootsuite
Vogelstein: Thus about 40% can be prevented; due to multiple dependencies of individual mutations. #AACR17
11:44am April 2nd 2017 via Hootsuite
Vogelstein: Environment, heredity. Now a third - last week https://t.co/npwJZHhelO random mutations. ~65% (etiology, not incidence) #AACR17
11:43am April 2nd 2017 via Hootsuite
Bert Vogelstein: #AACR17 MRD lays the foundation for a new type of adjuvant therapy trials '16 Science TM https://t.co/hk3EGTKnen
11:41am April 2nd 2017 via Hootsuite
Vogelstein: It takes years - perhaps decades - for mets to develop. Early det synergizes rather than competes w/new Rx #AACR17
11:40am April 2nd 2017 via Hootsuite
Vogelstein: Small amts of disease can be cured by chemotherapy. Micromets - close to 50% cure rate. With visible mets - close to 0 #AACR17
11:39am April 2nd 2017 via Hootsuite
Vogelstein: "Senior cancer scientist says "turn people into mice". Let's cut funding another 20%" (lazy journalist headline) #AACR17
11:38am April 2nd 2017 via Hootsuite
Vogelstein: A numbers game - mouse tumors are 1000-fold larger than humans. 'Turn humans into mice. Please don't tweet that!' #AACR17
11:37am April 2nd 2017 via Hootsuite
Vogelstein: "I am particularly good at curing mice... I'm not so good at curing people." Why - just arithmetic. #AACR17
11:36am April 2nd 2017 via Hootsuite
Vogelstein: Drug resistance: 100's to thousands of resistant cells already there, prior to Rx. In mice - situation different #AACR17
11:35am April 2nd 2017 via Hootsuite
Vogelstein: Two approaches are synergistic; shows famous Wagle vemurafenib photo '11 JCO https://t.co/5Mc4lez5Yx #AACR17
11:34am April 2nd 2017 via Hootsuite
Vogelstein: How to accomplish the next revolution: either new Rx, or (not as well recognized) new modes of prevention #AACR17
11:33am April 2nd 2017 via Hootsuite
Vogelstein: There is more to cancer than mutations: not all that have pneumococcus have pneumonia. If no pneumococcus, no pneumonia. #AACR17
11:32am April 2nd 2017 via Hootsuite
Vogelstein: There has been a revolution in cancer research - cancer results in the sequential accumulation of DNA alterations #AACR17
11:31am April 2nd 2017 via Hootsuite
Bert Vogelstein (Johns Hopkins, MD) Earlier detection as a key to lower cancer death rates #AACR17
11:30am April 2nd 2017 via Hootsuite
Caldas: TCR and neo-AG are significantly co-shared across metastasis (preliminary). #AACR17
11:28am April 2nd 2017 via Hootsuite
Caldas: Cluster samples based upon TCR repertoire, clustering depending on where the mets appear. Looked at phylogenetic trees #AACR17
11:27am April 2nd 2017 via Hootsuite
Caldas: TME can vary, genomic scars vary as well. #AACR17
11:23am April 2nd 2017 via Hootsuite
Caldas: Concludes - metastasis are generated, maintained and spread as communities of clones. Stem muts are freq sub-clonal #AACR17
Caldas: A consistent 'genomic scar' in lethal br cancer - could be in resp to cytotoxic Rx. Analysis in stem vs clade vs private #AACR17
11:19am April 2nd 2017 via Hootsuite
Caldas: Onto lethal mBrCa - heavily pre-treated, often 6 to 9 lines of trtmt. Landscape of drivers: about 100 mutation drivers. #AACR17
11:14am April 2nd 2017 via Hootsuite
Caldas: Dynamic changes of TME and neoAG load can predict response to cytotoxic Rx. #AACR17
11:12am April 2nd 2017 via Hootsuite
Caldas: In tumors that are resistant - muts in CNAs using 'Superfrag' tool; immune TME via RNAseq shows recruitment of resist cells #AACR17
11:11am April 2nd 2017 via Hootsuite
Caldas: Looking at ITH, TME in serial biopsies for neo-adjuvant Rx in ER+, TNBC, HER2+. ER+ slightly higher in TP53 #AACR17
11:09am April 2nd 2017 via Hootsuite
Caldas: Difference is prominent lymphocytic infiltration. '15 Cell https://t.co/luBN6pNyyy TME #AACR17
11:07am April 2nd 2017 via Hootsuite
Caldas: Landscapes of early br ca 11 distinct genomic subtypes '16 Nature Comm https://t.co/O8KrE5MQJb ITH varies sig across types #AACR17
11:06am April 2nd 2017 via Hootsuite
Caldas: Cancer is a community of cells, as a community of clones. 3 unpublished stories: dynamics of ITH/TME in neoadjuvant Rx; #AACR17
11:04am April 2nd 2017 via Hootsuite
Carlos Caldas (Cancer Research UK Cambridge UK) Breast cancer intratumor heterogeneity landscapes: what, when and where #AACR17
11:02am April 2nd 2017 via Hootsuite
Belcher: (Comment: Remarkable progress on the materials sciences and its intersection to detection, novel detection platforms) #AACR17
Belcher: Now can target human glioma targets, also T-cells in real-times for immunotherapy with other Ln-based materials #AACR17
11:00am April 2nd 2017 via Hootsuite
Belcher: Much smaller - from 980nm (wt) to 100nm (inho). Needed smaller carbon nanotubes; using DNA origami, self-assembling DNAs #AACR17
10:59am April 2nd 2017 via Hootsuite
Belcher: A 3D tracking system, whole animal, as small as 10 um. Looking at other types of cancer - M13 'small {lnho} phage probes' #AACR17
10:58am April 2nd 2017 via Hootsuite
Belcher: Now detect optically luminescent probes using hyperspectral and diffuse imaging (DOLPHIN) #AACR17
10:57am April 2nd 2017 via Hootsuite
Belcher: Now going back to further refine. Working on non-invasive removal of <0.2mm tumors, not enough data yet #AACR17
10:56am April 2nd 2017 via Hootsuite
Belcher: 10d post-surgery, clear difference. 3w others were missed, mouse dies at 5w. TP 98%; TN 71%. 40% OS improvement #AACR17
10:55am April 2nd 2017 via Hootsuite
Belcher: Showed video of real-time imaging, software can help analyze / segment tumors as small as 0.2mm Animal survival studies #AACR17
10:54am April 2nd 2017 via Hootsuite
Belcher: Thus tumors <1mm in size could be located and removed. Now to real-time imaging. #AACR17
10:53am April 2nd 2017 via Hootsuite
Belcher: Showed pre-surgical planning imaging, then post-unguided. Then goes in again, can remove more. (animal model) #AACR17
10:52am April 2nd 2017 via Hootsuite
Belcher: Unmet need - surgery debulking is done by eye. Gold std is contrast-enhanced CT. '14 PNAS https://t.co/2f5IE7buTW #AACR17
10:51am April 2nd 2017 via Hootsuite
Belcher: #AACR17 (For those watching at home - NSF video 'using viruses to make batteries' https://t.co/owHoFsWZhe )
10:49am April 2nd 2017 via Hootsuite
Belcher: OvCa majority dev drug resistance, OS has had little progress in past 30y. #AACR17
10:48am April 2nd 2017 via Hootsuite
Belcher: Less expensive than MRI, not CT (no radioactivity), using NIR optical detection. Ov Ca - 250K, 75% advanced stg #AACR17
Belcher: Took advantage of flourescence, 2nd-window NIR. Rolled up along w/the nanotube. Thus - when bound, M13 will light up tube #AACR17
10:47am April 2nd 2017 via Hootsuite
MT @gg_schwind: @kochinstitute @MIT Dr. Angela Belcher demonstrating that #cancer is like rocket science ... #AACR17 https://t.co/BzHJ7WQhlz
10:46am April 2nd 2017 via Hootsuite
RT @AEDeconinck: Engineer speaking in Opening Plenary #AACR17. Is this a first?? https://t.co/bzBxbOn7Y9
Belcher: Virus-powered cars, 'from energy to cancer'. Showed MnO4, Pd binding properties video #AACR17
10:45am April 2nd 2017 via Hootsuite
Belcher: Took a combinatorial approach, 1B comb's, did selection for peptide libraries. Huge list of Nature, Nature Materials pubs #AACR17
10:44am April 2nd 2017 via Hootsuite
